Hiring in life sciences? Share your open positions with our professional community. Read more Close

Advertisement

LUCAT1 promotes stemness in head and neck squamous cell carcinoma by sponging miR-128.

Created on 19 Jun 2026

Authors

Yifan Wen, Shuo Liu, Yaqing Mao, Ruifeng Li, Hui Yuh Soh, Yao Yu, Wen-Bo Zhang, Lingfei Jia, Xin Peng

Published in

Frontiers in oncology. Volume 16. Pages 1795813. Epub Jun 03, 2026.

Abstract

Head and neck squamous cell carcinoma (HNSCC) progression is well documented to be predominantly driven by a small subset of cancer stem cells (CSCs). These CSCs are implicated in recurrence, metastasis, dormancy, and therapy resistance. Therefore, targeting cancer stem cells has inspired the design of innovative treatment strategies. This study demonstrates that knockdown of the long non-coding RNA (lncRNA) LUCAT1 markedly reduces cancer cell stemness. This effect was confirmed across several experimental assays, including sphere-forming capacity and in vitro limiting dilution assays. Consequently, LUCAT1 knockdown potently suppresses HNSCC progression. Mechanistically, LUCAT1 functions as a competing endogenous RNA (ceRNA) to sponge miR-128, thereby relieving the post-transcriptional repression of downstream targets and promoting oncogenesis. Functional rescue assays show that restoration of miR-128 significantly reverses the antitumor efficacy of LUCAT1 knockdown on HNSCC cell. Moreover, miR-128 also attenuates the antitumor efficacy of LUCAT1 knockdown in both subcutaneous xenograft models and lymph node metastasis models in vivo. In agreement with previous results, BMI1 was identified as a direct and functionally relevant target of miR-128 in HNSCC cells. Collectively, these findings show that LUCAT1 constitutes a key regulatory component within the cancer stemness regulatory network of HNSCC, and underscores the function of the LUCAT1/miR-128 axis in sustaining stem cell-like traits and driving HNSCC malignant progression.

PMID:
42318476
Bibliographic data and abstract were imported from PubMed on 19 Jun 2026.

Read full publication at:
Please sign in to see all details.

Advertisement

Stats

  • Community rating n/a 0 votes
  • Reviewers' rating n/a 0 votes
  • Your rating

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

  • Recommendations n/a n/a positive of 0 vote(s)
  • Views 8
  • Comments 0

Recommended by

  • No recommendations yet.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.

Advertisement